Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer. / Thomsen, Maria; Kersten, Christian; Sorbye, Halfdan; Skovlund, Eva; Glimelius, Bengt; Pfeiffer, Per; Johansen, Julia S.; Kure, Elin H; Ikdahl, Tone; Tveit, Kjell Magne; Christoffersen, Thoralf; Guren, Tormod Kyrre.
In: OncoTarget, Vol. 7, No. 46, 2016, p. 75013-75022.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer
AU - Thomsen, Maria
AU - Kersten, Christian
AU - Sorbye, Halfdan
AU - Skovlund, Eva
AU - Glimelius, Bengt
AU - Pfeiffer, Per
AU - Johansen, Julia S.
AU - Kure, Elin H
AU - Ikdahl, Tone
AU - Tveit, Kjell Magne
AU - Christoffersen, Thoralf
AU - Guren, Tormod Kyrre
PY - 2016
Y1 - 2016
N2 - Objectives: The aim was to explore the prognostic significance of IL-6 and markers of systemic inflammatory response (SIR), in particular C-reactive protein (CRP), in metastatic colorectal cancer (mCRC) patients, in the total study population and according to RAS and BRAF mutation status. Results: High levels of pretreatment serum IL-6 or CRP were associated with impaired outcome, in terms of reduced PFS and OS. Patients with low versus high serum IL-6 levels had median OS of 26.0 versus 16.6 months, respectively (P < 0.001). Stratified according to increasing CRP levels, median OS varied from 24.3 months to 12.3 months, (P < 0.001). IL-6 and CRP levels affected overall prognosis also in adjusted analyses. The effect of IL-6 was particularly pronounced in patients with BRAF mutation (interaction P = 0.004). Materials and Methods: IL-6 and CRP were determined in pre-treatment serum samples from 393 patients included in the NORDIC-VII trial, in which patients with mCRC received first line treatment. The effect of serum IL-6 and CRP on progressionfree survival (PFS) and overall survival (OS) was estimated. Conclusions: High baseline serum consentrations of IL-6 or CRP were associated with impaired prognosis in mCRC. IL-6 and CRP give independent prognostic information in addition to RAS and BRAF mutation status.
AB - Objectives: The aim was to explore the prognostic significance of IL-6 and markers of systemic inflammatory response (SIR), in particular C-reactive protein (CRP), in metastatic colorectal cancer (mCRC) patients, in the total study population and according to RAS and BRAF mutation status. Results: High levels of pretreatment serum IL-6 or CRP were associated with impaired outcome, in terms of reduced PFS and OS. Patients with low versus high serum IL-6 levels had median OS of 26.0 versus 16.6 months, respectively (P < 0.001). Stratified according to increasing CRP levels, median OS varied from 24.3 months to 12.3 months, (P < 0.001). IL-6 and CRP levels affected overall prognosis also in adjusted analyses. The effect of IL-6 was particularly pronounced in patients with BRAF mutation (interaction P = 0.004). Materials and Methods: IL-6 and CRP were determined in pre-treatment serum samples from 393 patients included in the NORDIC-VII trial, in which patients with mCRC received first line treatment. The effect of serum IL-6 and CRP on progressionfree survival (PFS) and overall survival (OS) was estimated. Conclusions: High baseline serum consentrations of IL-6 or CRP were associated with impaired prognosis in mCRC. IL-6 and CRP give independent prognostic information in addition to RAS and BRAF mutation status.
KW - CRP
KW - IL-6
KW - mCRC
KW - Prognostic biomarker
KW - Survival
U2 - 10.18632/oncotarget.12601
DO - 10.18632/oncotarget.12601
M3 - Journal article
C2 - 27738330
AN - SCOPUS:84996607283
VL - 7
SP - 75013
EP - 75022
JO - Oncotarget
JF - Oncotarget
SN - 1949-2553
IS - 46
ER -
ID: 180937829